ABVC BioPharma, Inc. Common Stock (ABVC) — Analysis Summary
ABVC BioPharma, Inc. Common Stock (ABVC) has a market cap of $26.69M with year-over-year revenue growth of +0.0%. Net margin stands at -1551.9%. The stock trades at a P/E ratio of -3.8.
Key Takeaways
- Revenue changed +0.0% year-over-year
- Net margin of -1551.9%
- P/E ratio of -3.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ABVC posted revenue growth of +0.0% and trades at a P/E of -3.8.
ABVC BioPharma, Inc. Common Stock (ABVC)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -42.0x — earnings do not cover interest payments
Current ratio at 0.07x — severe short-term liquidity risk
Operating margin at -948.0% — severe operating losses
Net margin at -1034.1% — losses exceed revenue (possible one-time charges)
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
19
Headquarters
FREMONT, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
N/A
Dividend Yield
N/A
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.